Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.

Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors.

Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.